Successful management of eosinophilic chronic rhinosinusitis complicated by severe asthma using dupilumab, following negative initial results with benralizumab
Open Access
- 4 June 2020
- journal article
- letter
- Published by Elsevier BV in Allergology International
- Vol. 70 (1), 150-152
- https://doi.org/10.1016/j.alit.2020.05.002
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Eosinophilic chronic rhinosinusitisAllergology International, 2019
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaThe New England Journal of Medicine, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaThe New England Journal of Medicine, 2018
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2016
- Targeting the interleukin pathway in the treatment of asthmaThe Lancet, 2015
- Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC StudyAllergy, 2015
- Longitudinal increase in total IgE levels in patients with adult asthma: an association with poor asthma control.Respiratory Research, 2014
- Role of Interleukin-13 in AsthmaCurrent Allergy and Asthma Reports, 2013
- Smoking attenuates the age‐related decrease in IgE levels and maintains eosinophilic inflammationClinical & Experimental Allergy, 2012
- Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones.The Journal of Experimental Medicine, 1991